Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND). The study aims to evaluate the long-term safety and tolerability of rocatinlimab in patients with moderate-to-severe atopic dermatitis, a chronic skin condition that significantly impacts quality of life.
The intervention being tested is rocatinlimab, a drug administered via subcutaneous injection, designed to treat moderate-to-severe atopic dermatitis. The study also includes placebo groups for comparison.
This interventional study is randomized with a parallel assignment model and double masking, meaning both participants and investigators are unaware of which treatment is being administered. The primary purpose of the study is treatment-focused.
The study began on May 31, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on August 6, 2025. These dates are crucial for tracking the progress and expected outcomes of the study.
The update on this study could positively influence Amgen’s stock performance by showcasing the company’s commitment to addressing unmet medical needs in dermatology. Investors might view this as a strategic move to strengthen Amgen’s position in the competitive pharmaceutical market, especially against rivals focusing on similar conditions.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.